{"schema_version":"secwatch.filing_event.v1","accession":"0001799191-24-000020","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.556439+00:00","generated_at":"2026-05-31T09:46:37.741069+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives","bullets":["Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).","Gross profit $13M (-13.9%); gross margin 13.2% vs 18.8%; adjusted EBITDA ($8.7M) vs ($6.9M).","Dispensary segment revenue up 76% YoY; 10 capitation contracts signed in 2024 so far.","Company exploring strategic alternatives to maximize shareholder value.","Cash $46.4M; full year 2024 guidance updated, expecting H2 improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001799191-24-000020","json":"https://secwatch.observer/filing/0001799191-24-000020.json","markdown":"https://secwatch.observer/filing/0001799191-24-000020.md","text":"https://secwatch.observer/filing/0001799191-24-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/0001799191-24-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/toi-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:46:37.741069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}